IDX-1197

· Idience Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IDX-1197, covering 2026-04-17 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) [Phase 1, Phase 2]